Results 41 to 50 of about 9,311 (148)

Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation

Kidney Medicine, 2019
Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient ...
Priyamvada Singh, Hui Chen, Craig E. Gordon, Sandeep Ghai, J. Mark Sloan, Karen Quillen, Sara Moradi, Vipul Chitalia, Amitabh Gautam, Joel Henderson, Jean M. Francis   +10 more
doaj   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

Transplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval, Mohamed Eltemamy, Nabin K. Shrestha, Leal Herlitz, Emilio D. Poggio, Alvin C. Wee   +5 more
wiley   +1 more source

Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement

eJHaem
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear.
Benjamin J. Lee, Zhaohui Arter, Jean Doh, Shawn P. Griffin, Pongthep Vittayawacharin, Steven Atallah, Kevin R. Shieh, Minh‐Ha Tran, Sonata Jodele, Piyanuch Kongtim, Stefan O. Ciurea   +10 more
doaj   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Annals of Clinical and Translational Neurology, EarlyView.
Francesco Saccà, Ryan Pelto
wiley   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, EarlyView.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

Myelitis‐Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late‐Onset Neuromyelitis Optica Spectrum Disorders

Annals of Neurology, Volume 99, Issue 5, Page 1139-1151, May 2026.
Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu, Jin‐Zhou Feng, Hua‐Xing Meng, Hai‐Bing Xiao, Xiao‐Ling Li, Jin Zhen, Wen‐Ying Lu, Xu‐Ming Xi, Ti Wu, Bao‐Shi Yuan, Mo‐Li Fan, Chao Zhang, De‐Cai Tian, Xia Meng, Fu‐Dong Shi, Tian Song   +15 more
wiley   +1 more source

Role for Complement C5 in Eosinophilic Inflammation of Severe Asthma

Allergy, Volume 81, Issue 5, Page 1571-1586, May 2026.
Complement activation module, particularly C5, is positively associated with eosinophilic inflammation in severe asthma cohorts. Elevated C5 expression correlates with poor lung function improvement and persistent eosinophilic inflammation. Mouse model studies confirm that C5 exacerbates eosinophilic inflammation, highlighting its potential as a ...
Cong Dong, Shaohua Lu, Zhenan Deng, Xuliang Cai, Huahao Shen, Guochao Shi, Changxing Ou, Zuofu Peng, Wei Jiang, Xiuhua Fu, Changzheng Wang, Meiling Jin, Zhongmin Qiu, Xiaoyang Wei, Wei Gu, Kewu Huang, Qiang Li, Xiangyan Zhang, Nanshan Zhong, Kian Fan Chung, Qingling Zhang, on behalf of C‐BIOPRED Consortium, Jiangtao Lin, Yongming Zhang, Nan Su, Xiaoyan Zhang, Qing Zhao, Ying Nong, Ping Chen, Tianyi Zhu, Binbin Ji, Yan Wang, Haitao Zhao, Jinbao Wang, Zhiyuan Zhang, Xiaona Yang, Chunhua Wei, Jing Han, Nong Yu, Qiang Li, Zhifu Yang, Yanhong Liu, Guohua Li, Huadong Guan, Shuping Zhang, Xiuhua Fu, Lihong Wang, Lingxin Meng, Zhenting Sun, Guangqin Cao, Lei Zhao, Kewu Huang, Hong Zhang, Wen Wang, Li An, Yangyu Chen, Yanli Gao, Xiaoxia Liu, Huifen Zhai, Fang Lin, Zhaohui Zhong, Zhongguang Wen, Yan Xiao, Jian Kang, Linfei Kong, Xinming Su, Xue Yan, Dijia Zhou, Huaping Tang, Wei Han, Yi Shu, Tintian Li, Lixin Xie, Hong Hu, Bo Liu, Yuzhu Li, Longmei Fan, Yue Zhang, Shifeng Zhao, Xiaofang Liu, Yuhong Wang, Xichun Zhang, Xinmao Wang, Pen Bai, Guangfa Wang, Yan Hu, Zhanwei Hu, Ju Cao, Bei He, Rui Wu, Xiaoyan Gai, Hong Zhu, Zhihai Han, Jiyi Meng, Wei Chen, Li Ma, Zhenqian Liu, Chunyang Zhang, Yan Zhang, Huahao Shen, Fugui Yan, Bin Shen, Xinghong Wang, Hao Zhang, Yinghua Yin, Jinkai Liu, Yanxiong Mao, Mao Huang, Xin Yao, Mao Huang, Ji Zhou, Zhenzhen Wu, Ping Yan, Yujie Zhang, Xinling Yang, Ningfei Ji, Fan Fei, Wanzhen Fu, Yi Yang, Yuting Shi, Wangjian Cha, Guochao Shi, Min Zhou, Wei Tang, Wei Chen, Jun Zhou, Wenjie Yang, Lei Zhu, Meiling Jin, Liping Xue, Li Li, Chun Li, Yin Gong, Qiang Li, Guogang Xie, Luhong Bao, Wuping Bao, Nianyun Li, Fengming Ding, Min Zhang, Zhongmin Qiu, Li Yu, Jungang Xie, Lingling Yi, Xianghuai Xu, Qiang Chen, Junjun Tang, Jinfu Xu, Xiaobing Ji, Jingyun Shi, Bo Su, Xiaojun Yang, Jiuwen Bai, Shuo Liang, Kebing Cheng, Wei Gu, Jiyong Ma, Yun Liu, Jun Ren, Shan Mao, Qingling Zhang, Baoqing Sun, Jiaxing Xie, Rihuang Qiu, Zhiqiang Wang, Peiyan Zhen, Wenting Luo, Changgao Zhong, Wei Luo, Yanqing Xie, Xinxin Yu, Wenting Yu, Wei He, Changzheng Wang, Qianli Ma, Min Wan, Mingzhou Zhang, Haining Li, Shaoxi Cai, Haijin Zhao, Yanmei Ye, Fang Zhou, Laiyu Liu, Guohua Huang, Jianpeng Liang, Jianping Zhao, Jungang Xie, Qiongjie Hu, Kaiyan Li, Wang Ni, Guohua Zheng, Weining Xiong, Lingling Yi, Xihu Du, Yunhui Zhang, Zhi Li, Xiaoqiong Tan, Feng Liao, Shenglan Wang, Yijiang Huang, Xinjun Cai, Kai Liu, Shaojing Sheng, Yihui Fu, Shenghua Sun, Qiang Zhang, Jinweng Cai, Ye Ling, Pin Chen, Hong Luo, Lv Liu, Zhijun Liu, Yuling Tang, Yusheng Yan, Guiyan Mo, Long Wen, Yinqun Zhu, Du Fan   +217 more
wiley   +1 more source

The Complement System in Post‐Transplant Kidney Injury

Organ Medicine, EarlyView.
Mengsi Hu
wiley   +1 more source